



## Commentary

## Does IMPROVE-IT prove it?



Robert DuBroff

Division of Cardiology, University of New Mexico, MSC10-5550, Albuquerque, NM 87131-0001, USA

## ARTICLE INFO

Available online 11 January 2016

## ABSTRACT

The recently published IMPROVE-IT trial has been hailed as proof that lowering cholesterol reduces the risk of cardiovascular disease (Cannon et al., 2015). Although this study did demonstrate a modest clinical benefit with incremental low-density lipoprotein cholesterol lowering, many physicians tend to ignore the numerous clinical studies which have failed to demonstrate a benefit of cholesterol lowering. This article challenges the cholesterol hypothesis by reviewing these negative studies and our reluctance to acknowledge them. Paradoxically, cholesterol lowering remains the focus of cardiovascular disease prevention despite the inconsistent benefit demonstrated in dozens of clinical trials. The cholesterol-lowering, statin-centric approach to cardiovascular disease prevention may in fact distract us from other beneficial therapies. Dr. Alexander Leaf, former chief of medicine at Massachusetts General Hospital, commented on this paradox and the Lyon Diet Heart Study nearly 15 years ago by writing, "At a time when health professionals, the pharmaceutical industries, and the research funding and regulatory agencies are almost totally focused on lowering plasma cholesterol levels by drugs, it is heartening to see a well-conducted study finding that relatively simple dietary changes achieved greater reductions in risk of all-cause and coronary heart disease mortality in a secondary prevention trial than any of the cholesterol-lowering studies to date" (Leaf, 1999).

© 2016 Elsevier Inc. All rights reserved.

For nearly twenty years, cholesterol lowering has been the mainstay of many CVD prevention guidelines for both primary and secondary prevention. The IMPROVE-IT trial, recently published in the *New England Journal of Medicine*, was a large randomized trial of cholesterol lowering with the statin drug simvastatin versus simvastatin plus ezetimibe (a cholesterol absorption inhibitor) in patients with a recent acute coronary syndrome (Cannon et al., 2015). The hypothesis tested was not simply whether the simvastatin–ezetimibe combination is superior to simvastatin alone, but rather, if incremental lowering of LDL cholesterol results in further clinical benefit. At issue is the validity of the cholesterol hypothesis, which links cholesterol intake and blood levels to CVD and posits that lowering cholesterol reduces the likelihood of CVD for both primary and secondary prevention. The inconvenient truth, however, is that cholesterol lowering does not consistently save lives or reduce the risk of CVD.

**Association does not equal causation**

Elevated serum cholesterol levels are universally identified as a major risk factor for atherosclerotic disease. Ideally a cardiovascular risk factor should help us distinguish those who will develop CVD from those who will not. However, the distribution of cholesterol levels

in individuals who did and did not develop coronary heart disease in the original Framingham Heart Study are remarkably similar except when total cholesterol is extremely high (>380 mg/dl) or extremely low (<150 mg/dl; Fig. 1) (Kannel et al., 1979). Risk factors may be associated with a disease, but that does not prove causation (Hill, 1965). For example, high levels of triglycerides and low levels of HDL cholesterol are considered cardiovascular risk factors, but treatments to correct these lipid abnormalities have failed to demonstrate a consistent clinical benefit (The FIELD Study Investigators, 2005; Michos et al., 2012). Hence, risk factors should not automatically become treatment targets, and treatment of surrogate endpoints is not without hazard.

**Lower cholesterol levels are not always better**

In general, there are three ways to achieve lower cholesterol levels. First, one can be born with genetically low cholesterol. Mendelian randomization studies have shown that people born with genetically low cholesterol levels are at lower risk of CVD, but it is unclear if this is due to association or causation (Ference et al., 2012). Nevertheless, we should not extrapolate these results to the broader population who lack these genetic variations. More commonly, diet and drugs are used to lower cholesterol levels. The low-fat diet has been recommended for decades but has never been proven to prevent CVD. The Women's Health Initiative Randomized Controlled Dietary Modification Trial was a primary prevention study of 48,835 postmenopausal women

E-mail address: [rodubroff@salud.unm.edu](mailto:rodubroff@salud.unm.edu).




Fig. 1. Serum cholesterol levels (mg/dl) in individuals who did and did not develop coronary heart disease (CHD) from the Framingham Heart Study (Kannel et al., 1979). Reprinted with permission of the publisher.

randomized to either a low-fat diet or control diet. No reduction in cardiovascular events was observed after 8.1 years (Howard et al., 2006). An exhaustive review and meta-analysis of 72 dietary clinical trials concluded that reduced consumption of saturated fats does not reduce cardiovascular mortality (Chowdhury et al., 2014). Early studies of cholesterol lowering with bile acid sequestrants, fibrates, and niacin suggested clinical benefit, but the 2013 AHA/ACC guidelines on cholesterol management concluded that only statins have been proven to reduce cardiovascular events and mortality rates (Stone et al., 2014). If the cholesterol hypothesis is correct, why aren't these cholesterol-lowering diets and drugs equally effective? While many statin trials and meta-analyses have concluded that there is significant benefit, others have concluded otherwise. The Cholesterol Treatment Trialists meta-analysis of 27 statin trials in people at low risk of vascular disease concluded that there is a clear benefit, but a subsequent meta-analysis of the same 27 studies concluded there was no significant mortality benefit (Cholesterol Treatment Trialists' (CTT) Collaborators, 2012; Abramson et al., 2013). Similarly, a meta-analysis of 11 statin trials involving 65,229 participants in high-risk primary prevention found no mortality benefit (Ray et al., 2010). Other examples where cholesterol lowering trials have failed to demonstrate either a reduction in mortality or clinical events include statins in the elderly (primary prevention group) (Shepherd et al., 2002), statins in moderately hypercholesterolemic, hypertensive patients (primary and secondary prevention) (ALLHAT-LLT Authors, 2002), statins in heart failure (primary and secondary prevention) (Kjekshus et al., 2007; GISSI-HF Investigators, 2008), statins in renal failure (primary and secondary prevention) (Wanner et al., 2005; Fellstrom et al., 2009), statins in diabetes (primary and secondary prevention) (Wanner et al., 2005; Knopp et al., 2006), statins in individuals with extremely high coronary calcium scores (secondary prevention) (Arad et al., 2005), lipid lowering in peripheral vascular disease (secondary prevention) (Aung et al., 2007), statins in acute coronary syndromes (secondary prevention) (Vale et al., 2014), and statins post-coronary bypass (secondary prevention) (The Post Coronary Artery Bypass Graft Trial Investigators, 1997).

These contradictory and confusing results have engendered two schools of thought. The predominant view is that positive statin trials provide unequivocal proof of benefit. Proponents dismiss or refute negative statin trials by arguing that the degree of LDL lowering was inadequate, these studies were not designed or powered to reduce mortality, there were methodological errors, the negative results are due to a type II statistical error, or simply argue that the statins were started too late in the course of the disease. Conversely, some clinicians believe that statin drugs are ineffective in reducing mortality or CVD (de Lorgeril, 2014). They rebut the positive statin trials by arguing the trials were

overseen by the pharmaceutical industry, many trials were stopped prematurely, there were methodological errors and biases, the positive results are due to a type I statistical error, or there is an over-reliance on combined endpoints and meta-analyses rather than mortality rates. I believe there is a third option. We can reconcile these discordant views by acknowledging that statin drugs do reduce mortality and CVD in certain individuals, but we are currently unable to accurately identify these individuals. Optimistically, future research may help us identify individuals who should or should not be treated with statin drugs based upon pharmacogenomics rather than biochemical or clinical characteristics.

**Mortality results are more important than combined endpoints**

The primary endpoint of the IMPROVE-IT trial was the combined endpoint of cardiovascular death, non-fatal MI, hospital admission for unstable angina, coronary revascularization after 30 days, or non-fatal stroke. While the avoidance of a stroke or heart attack is extremely important, combined endpoints may distract us from total mortality. By combining endpoints of unequal importance a positive result may lead to an exaggerated perception of benefit (Ferreira-González et al., 2007). In IMPROVE-IT, only two of the five components of the composite endpoint (non-fatal MI and stroke) achieved statistical significance, yet the study is considered positive because the primary end point achieved statistical significance (P = 0.016; HR, 0.936; 95% CI, 0.89–




Fig. 2. Comparison of clinical benefit to degree of LDL lowering in IMPROVE-IT and statin trials of patients with acute coronary syndromes. The combined clinical endpoint includes death, non-fatal MI, or non-fatal stroke as defined in the Cochrane meta-analysis of statin trials in acute coronary syndromes (Vale et al., 2014).

0.99). Notably, there was no significant mortality benefit after seven years ( $P = 0.78$ ; HR, 0.99; 95% CI, 0.91–1.07).

### Clinical benefits don't correlate with the degree of LDL lowering

The IMPROVE-IT trial authors state that their findings are consistent with prior statin trials in which the degree of LDL lowering correlates with the degree of clinical benefit. To support this statement, they compare their results to 14 other statin trials by plotting the degree of LDL reduction versus the reduction in major vascular events (Baigent et al., 2005). Their graphical conclusion suggests a linear relation between LDL lowering and clinical benefit. However, only three of these 14 studies reported a mortality benefit of statin therapy (LIPID Study Group, 1998; Anon, 1994; Heart Protection Study Collaborative Group, 2002) while three of the studies reported no significant clinical benefit at all (The Post Coronary Artery Bypass Graft Trial Investigators, 1997; GISSI Prevenzione Investigators, 2000; Holdaas et al., 2003). It seems illogical to argue that these 14 clinical trials support the cholesterol hypothesis when several of these studies actually contradict it. Furthermore, the 14 studies chosen for comparison represent a diverse group of patient populations different from IMPROVE-IT and included primary prevention, secondary prevention, hypertension, renal transplantation, prior percutaneous coronary intervention, elderly, prior coronary bypass surgery, and diabetes. A more appropriate and logical comparison group would be other statin trials involving patients with acute coronary syndromes. A recent Cochrane meta-analysis of statin therapy for acute coronary syndromes readily provides the data needed for such a comparison (Vale et al., 2014). Fig. 2 illustrates this comparison and shows no correlation between the degree of LDL lowering and the degree of clinical benefit. Although not statistically significant, the trend line actually suggests an inverse relationship between LDL lowering and the degree of clinical benefit. It is noteworthy that this Cochrane meta-analysis was published before IMPROVE-IT and included studies of shorter duration, but nonetheless concluded that there is no benefit of statin therapy in either the combined clinical endpoint or total mortality. The lack of correlation between LDL lowering and mortality benefit was also demonstrated in a meta-analysis of 11 statin trials in high-risk primary prevention (Ray et al., 2010).

### Cardiovascular disease can be dramatically reduced without targeting or reducing cholesterol

The cholesterol-lowering, statin-centric approach to CVD prevention may also distract us from other proven therapies. Twenty years ago, the Lyon Diet Heart Study, a randomized trial of the Mediterranean diet compared to no dietary intervention beyond the advice of the patients' attending physician, reported a 70% mortality reduction in patients with a prior myocardial infarction (de Lorgeril et al., 1994). The benefits of the Mediterranean diet have also been confirmed in multiple other studies (Sofi et al., 2010). The benefits of a healthy diet and lifestyle were also seen in The Nurses' Health Study, which reported a 92% relative risk reduction in sudden cardiac death among nurses who followed a Mediterranean diet, did not smoke, exercised regularly, and maintained a BMI < 25 compared to nurses who did not (Chiuve et al., 2011). Similarly, a recent prospective cohort study of Swedish men concluded that almost four of five heart attacks could be prevented by adhering to a healthy diet, moderate alcohol intake, regular exercise, and avoiding abdominal adiposity (Åkesson et al., 2014). While some might speculate that the benefits reported in these studies may be attributed to lower cholesterol levels, it is noteworthy that the cholesterol levels in patients randomized to the Mediterranean diet in the Lyon Diet Heart Study were unchanged.

Nobel laureates Brown and Goldstein predicted the elimination of coronary disease in their 1996 *Science* editorial, "Exploitation of recent breakthroughs—proof of the cholesterol hypothesis, discovery of effective drugs, and better definition of genetic susceptibility factors—may

well end coronary disease as a major public health problem early in the next century" (Brown and Goldstein, 1996). History has proven otherwise. Despite worldwide statin usage and cholesterol-lowering campaigns, the prevalence of coronary heart disease has reached pandemic proportions. By selectively relying upon those studies that validate the cholesterol hypothesis while ignoring or finding fault with studies that do not, we are failing to be objective. This reluctance to acknowledge anomalies in a theory is well described by Thomas Kuhn in his book, *The Structure of Scientific Revolutions*, and can hinder the rejection of an old theory and impede the development of a new one (Kuhn, 1970). After twenty years, we must concede that not all the facts fit the theory and we should heed the wisdom of Dr. Leaf (Leaf, 1999).

No funding was received for this manuscript.

### Conflict of interest statement

No conflicts of interest to declare.

### References

- Abramson, J.D., Rosenberg, H.G., Jewell, N., Wright, J.M., 2013. Should people at low risk of cardiovascular disease take a statin? *BMJ* 347, f6123.
- Åkesson, A., Larsson, S.C., Discacciati, A., Wolk, A., 2014. Low-risk diet and lifestyle habits in the primary prevention of myocardial infarction in men. A population-based prospective cohort study. *J. Am. Coll. Cardiol.* 64, 1299–1306.
- ALLHAT-LLT authors, 2002. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. *JAMA* 288, 2998–3007.
- Anon, 1994. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 344, 1383–1389.
- Arad, Y., Spadaro, L.A., Roth, M., Newstein, D., Guerci, A.D., 2005. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. *J. Am. Coll. Cardiol.* 46, 166–172.
- Aung, P.P., Maxwell, H., Jepson, R.G., Price, J., Leng, G.C., 2007. Lipid-lowering for peripheral arterial disease of the lower limb (review). *Cochrane Library* 4, 1–61.
- Baigent, C., Keech, A., Kearney, P.M., et al., 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 366, 1267–1278.
- Brown, M.S., Goldstein, J.L., 1996. Heart attacks: gone with the century? *Science* 272 (5262), 629.
- Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al., 2015. Ezetimibe added to statin therapy after acute coronary syndromes. *N. Engl. J. Med.* 372, 2387–2397.
- Chiuve, S.E., Fung, T.T., Rexrode, K.M., et al., 2011. Adherence to a low-risk, healthy lifestyle and risk of sudden cardiac death among women. *JAMA* 306 (1), 62–69.
- Cholesterol Treatment Trialists' (CTT) Collaborators, 2012. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomized trials. *Lancet* 380, 581–590.
- Chowdhury, R., Warnakula, S., Kunutsor, S., et al., 2014. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. *Ann. Intern. Med.* 160 (6), 398–406.
- de Lorgeril, M., 2014. Cholesterol and Statins. *Sham Science and Bad Medicine*. Thierry Souccar Publishing, Vergèze.
- de Lorgeril, M., Renaud, S., Mamelle, N., et al., 1994. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. *Lancet* 343, 1454–1459 (Erratum in: *Lancet* 1995;345:738).
- Fellstrom, B.C., Jardine, A.G., Schmieder, R.E., et al., 2009. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *N. Engl. J. Med.* 360, 1395–1407.
- Ference, B.A., Yoo, W., Alesh, I., et al., 2012. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. *J. Am. Coll. Cardiol.* 60 (25), 2631–2639.
- Ferreira-González, I., Busse, J.W., Heels-Ansdell, D., et al., 2007. Problems with use of composite end points in cardiovascular trials: systematic review of randomized controlled trials. *BMJ* 334, 786.
- GISSI Prevenzione Investigators, 2000. Results of the low-dose (20 mg) Pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? *Ital. Heart J.* 1, 810–820.
- GISSI-HF investigators, 2008. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. *Lancet* 372, 1231–1239.
- Heart Protection Study Collaborative Group, 2002. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. *Lancet* 360, 7–22.
- Hill, A.B., 1965. The environment and disease: association or causation? *Proc. R. Soc. Med.* 58 (5), 295–300.
- Holdaas, H., Fellstrom, B., Jardine, A.G., et al., 2003. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomized, placebo-controlled trial. *Lancet* 361, 2024–2031.
- Howard, B.V., Van Horn, L., Hsia, J., et al., 2006. Low-fat dietary pattern and risk of cardiovascular disease. The Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA* 295, 655–666.

- Kannel, W.B., Castelli, W.P., Gordon, T., 1979. Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Study. *Ann. Intern. Med.* 90 (1), 85–91.
- Kjekshus, J., Apetrei, E., Barrios, V., et al., 2007. Rosuvastatin in older patients with systolic heart failure. *N. Engl. J. Med.* 357, 2248–2261.
- Knopp, R.H., d'Emden, M., Smilde, J.G., Pocock, S.J., 2006. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). *Diabetes Care* 29, 1478–1485.
- Kuhn, T.S., 1970. *The Structure of Scientific Revolutions*. The University of Chicago Press, Chicago, IL.
- Leaf, A., 1999. Dietary prevention of coronary heart disease: the Lyon Diet Heart Study. *Circulation* 99 (6), 733–735.
- LIPID Study Group, 1998. Prevention of CV events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N. Engl. J. Med.* 339, 1349–1357.
- Michos, E.D., Sibley, C.T., Baer, J.T., Blaha, M.J., Blumenthal, R.S., 2012. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events. *J. Am. Coll. Cardiol.* 59 (23), 2058–2064.
- Ray, K.K., Seshasai, S.R., Erqou, S., et al., 2010. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. *Arch. Intern. Med.* 170 (12), 1024–1031.
- Shepherd, J., Blauw, G.J., Murphy, M.B., et al., 2002. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomized controlled trial. *Lancet* 360, 1623–1630.
- Sofi, F., Abbate, R., Gensini, G.F., Casini, A., 2010. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systemic review and meta-analysis. *Am. J. Clin. Nutr.* 92 (5), 1189–1196.
- Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al., 2014. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J. Am. Coll. Cardiol.* 63, 2889–2934.
- The FIELD Study Investigators, 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. *Lancet* 366, 1849–1861.
- The Post Coronary Artery Bypass Graft Trial Investigators, 1997. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. *N. Engl. J. Med.* 336, 153–162.
- Vale, N., Nordmann, A.J., Schwartz, G.G., et al., 2014. Statins for acute coronary syndrome (review). *Cochrane Library* 9, 1–122.
- Wanner, C., Krane, V., Marz, W., et al., 2005. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N. Engl. J. Med.* 353, 238–248.